U S PHYSICAL THERAPY INC /NV (USPH) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
58/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseUSPH / S&P -7.70% / 15.20% |
LoseUSPH / S&P 11.32% / 15.00% |
LoseUSPH / S&P -92.14% / 50.40% |
| 2026-Q12/3 |
WinUSPH / S&P -3.44% / -4.33% |
WinUSPH / S&P 13.73% / 11.30% |
LoseUSPH / S&P -76.61% / 27.70% |
| 2025-Q41/3 |
LoseUSPH / S&P -7.49% / 2.65% |
WinUSPH / S&P 16.33% / 9.00% |
LoseUSPH / S&P -22.28% / 13.40% |
| 2025-Q33/3 |
WinUSPH / S&P 9.21% / 8.12% |
WinUSPH / S&P 17.50% / 4.61% |
WinUSPH / S&P 170.45% / 13.45% |
| 2025-Q22/3 |
LoseUSPH / S&P 8.72% / 10.94% |
WinUSPH / S&P 16.24% / 4.83% |
WinUSPH / S&P 129.00% / 10.63% |
| 2025-Q12/3 |
LoseUSPH / S&P -17.95% / -4.27% |
WinUSPH / S&P 14.30% / 4.98% |
WinUSPH / S&P 86.32% / 10.57% |
| 2024-Q43/3 |
WinUSPH / S&P 5.33% / 2.41% |
WinUSPH / S&P 11.00% / 5.25% |
WinUSPH / S&P 42.64% / 6.15% |
| 2024-Q31/3 |
LoseUSPH / S&P -7.94% / 5.89% |
WinUSPH / S&P 9.22% / 5.89% |
LoseUSPH / S&P -48.54% / 6.11% |
| 2024-Q21/3 |
LoseUSPH / S&P -17.78% / 4.28% |
WinUSPH / S&P 8.07% / 5.38% |
LoseUSPH / S&P -47.92% / 5.12% |
| 2024-Q12/3 |
WinUSPH / S&P 21.69% / 10.56% |
WinUSPH / S&P 7.37% / 5.71% |
LoseUSPH / S&P -45.58% / 5.59% |
| 2023-Q41/3 |
LoseUSPH / S&P 2.04% / 11.69% |
WinUSPH / S&P 9.34% / 6.81% |
LoseUSPH / S&P -42.41% / 7.78% |
| 2023-Q31/3 |
LoseUSPH / S&P -24.11% / -3.27% |
WinUSPH / S&P 9.12% / 7.52% |
LoseUSPH / S&P -42.62% / -5.03% |
| 2023-Q22/3 |
WinUSPH / S&P 24.46% / 8.74% |
WinUSPH / S&P 9.98% / 9.50% |
LoseUSPH / S&P -34.25% / -8.57% |
| 2023-Q12/3 |
WinUSPH / S&P 21.38% / 7.50% |
WinUSPH / S&P 10.81% / 10.77% |
LoseUSPH / S&P -25.09% / -15.69% |
| 2022-Q41/3 |
LoseUSPH / S&P 7.11% / 7.56% |
LoseUSPH / S&P 11.74% / 11.88% |
WinUSPH / S&P -7.05% / -17.99% |
| 2022-Q31/3 |
LoseUSPH / S&P -30.06% / -4.88% |
LoseUSPH / S&P 12.25% / 13.47% |
WinUSPH / S&P 25.74% / -1.41% |
| 2022-Q22/3 |
WinUSPH / S&P 10.25% / -16.10% |
LoseUSPH / S&P 13.40% / 13.71% |
WinUSPH / S&P 25.86% / 11.04% |
| 2022-Q12/3 |
WinUSPH / S&P 4.53% / -4.60% |
WinUSPH / S&P 21.71% / 15.97% |
LoseUSPH / S&P 15.26% / 42.23% |
| 2021-Q41/3 |
LoseUSPH / S&P -13.28% / 11.03% |
WinUSPH / S&P 17.04% / 15.00% |
LoseUSPH / S&P -2.82% / 96.40% |
| 2021-Q31/3 |
LoseUSPH / S&P -4.21% / 0.58% |
WinUSPH / S&P 12.87% / 10.77% |
LoseUSPH / S&P USPH unavailable / 69.42% |
| 2021-Q22/3 |
WinUSPH / S&P 11.65% / 8.55% |
WinUSPH / S&P 6.82% / 6.58% |
LoseUSPH / S&P USPH unavailable / 51.81% |
| 2021-Q10/3 |
LoseUSPH / S&P -13.18% / 6.17% |
LoseUSPH / S&P -11.67% / -1.06% |
LoseUSPH / S&P USPH unavailable / 7.39% |
| 2020-Q41/3 |
WinUSPH / S&P 38.41% / 12.15% |
LoseUSPH / S&P -12.24% / -3.72% |
LoseUSPH / S&P USPH unavailable / -33.42% |
| 2020-Q30/3 |
LoseUSPH / S&P 7.23% / 8.93% |
LoseUSPH / S&P -10.39% / -2.04% |
LoseUSPH / S&P USPH unavailable / -27.10% |
| 2020-Q20/3 |
LoseUSPH / S&P 17.42% / 20.54% |
LoseUSPH / S&P -7.85% / -0.46% |
LoseUSPH / S&P USPH unavailable / -27.11% |
| 2020-Q11/3 |
LoseUSPH / S&P -39.45% / -19.60% |
WinUSPH / S&P 3.61% / 3.47% |
LoseUSPH / S&P USPH unavailable / -14.75% |
| 2019-Q41/3 |
LoseUSPH / S&P -12.18% / 9.07% |
WinUSPH / S&P 6.18% / 5.36% |
LoseUSPH / S&P USPH unavailable / 2.99% |
| 2019-Q32/3 |
WinUSPH / S&P 6.75% / 1.70% |
WinUSPH / S&P 7.05% / 5.02% |
LoseUSPH / S&P USPH unavailable / 0.21% |
| 2019-Q22/3 |
WinUSPH / S&P 16.97% / 4.30% |
WinUSPH / S&P 8.58% / 6.64% |
LoseUSPH / S&P USPH unavailable / 8.65% |
| 2019-Q11/3 |
LoseUSPH / S&P 2.88% / 13.65% |
WinUSPH / S&P 8.70% / 8.12% |
LoseUSPH / S&P USPH unavailable / 14.29% |
| 2018-Q41/3 |
LoseUSPH / S&P -13.53% / -13.52% |
WinUSPH / S&P 9.63% / 9.05% |
LoseUSPH / S&P USPH unavailable / 18.23% |
| 2018-Q32/3 |
WinUSPH / S&P 23.80% / 7.71% |
WinUSPH / S&P 12.65% / 10.21% |
LoseUSPH / S&P USPH unavailable / 19.06% |
| 2018-Q22/3 |
WinUSPH / S&P 18.38% / 3.43% |
WinUSPH / S&P 14.34% / 9.03% |
LoseUSPH / S&P USPH unavailable / 14.46% |
| 2018-Q12/3 |
WinUSPH / S&P 12.92% / -0.76% |
WinUSPH / S&P 15.69% / 7.68% |
LoseUSPH / S&P USPH unavailable / 12.46% |
| 2017-Q42/3 |
WinUSPH / S&P 17.84% / 6.64% |
WinUSPH / S&P 16.13% / 7.03% |
LoseUSPH / S&P USPH unavailable / 13.82% |
| 2017-Q31/3 |
LoseUSPH / S&P 2.08% / 4.48% |
WinUSPH / S&P 12.29% / 5.68% |
LoseUSPH / S&P USPH unavailable / 17.57% |
| 2017-Q21/3 |
LoseUSPH / S&P -6.93% / 3.09% |
WinUSPH / S&P 9.45% / 4.83% |
LoseUSPH / S&P USPH unavailable / 17.74% |
| 2017-Q11/3 |
LoseUSPH / S&P -6.98% / 6.07% |
WinUSPH / S&P 7.69% / 3.67% |
LoseUSPH / S&P USPH unavailable / 13.32% |
| 2016-Q42/3 |
WinUSPH / S&P 12.27% / 3.82% |
WinUSPH / S&P 7.62% / 2.09% |
LoseUSPH / S&P USPH unavailable / 7.05% |
| 2016-Q33/3 |
WinUSPH / S&P 4.43% / 3.85% |
WinUSPH / S&P 8.78% / 0.20% |
WinUSPH / S&P 14.12% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | USPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -2.11% | 20.78% |
| Annualized return | -2.11% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | USPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -25.83% | 83.14% |
| Annualized return | -5.80% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | USPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 45.24% | 319.30% |
| Annualized return | 3.80% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |